Yuichi J Shimada
Overview
Explore the profile of Yuichi J Shimada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Osawa I, Akita K, Hasegawa K, Fifer M, Tower-Rader A, Reilly M, et al.
Circ Heart Fail
. 2025 Jan;
18(2):e012343.
PMID: 39831317
Background: Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy and causes major adverse cardiovascular events (MACE). SVEP1 (Sushi, von Willebrand factor type A, epidermal growth factor, and pentraxin domain containing...
2.
Akita K, Suwa K, Ohno K, Weiner S, Tower-Rader A, Fifer M, et al.
Int J Cardiol
. 2024 Dec;
421():132911.
PMID: 39706305
Background: Late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) in hypertrophic cardiomyopathy (HCM) typically represents myocardial fibrosis and may lead to fatal ventricular arrhythmias. However, CMR is resource-intensive and...
3.
Lu R, Lumish H, Hasegawa K, Maurer M, Reilly M, Weiner S, et al.
Eur J Heart Fail
. 2024 Dec;
27(2):275-284.
PMID: 39694602
Aims: Atrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), leading to increased symptom burden and risk of thromboembolism. The HCM-AF score was developed...
4.
Akita K, Maurer M, Tower-Rader A, Fifer M, Shimada Y
Circ Heart Fail
. 2024 Nov;
18(1):e012434.
PMID: 39523983
Background: Distinguishing hypertrophic cardiomyopathy (HCM) from other cardiomyopathies with left ventricular hypertrophy (LVH), such as hypertensive LVH, transthyretin amyloid cardiomyopathy, and aortic stenosis, is sometimes challenging. Using plasma proteomics profiling,...
5.
Lumish H, Harano N, Liang L, Hasegawa K, Maurer M, Tower-Rader A, et al.
Europace
. 2024 Oct;
26(11).
PMID: 39441047
Aims: Atrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), increasing symptom burden and stroke risk. We aimed to construct a plasma proteomics-based model...
6.
Akita K, Kusunose K, Haga A, Shimomura T, Kosaka Y, Ishiyama K, et al.
Echo Res Pract
. 2024 Oct;
11(1):23.
PMID: 39396969
Background: Hypertrophic cardiomyopathy (HCM) can cause myocardial fibrosis, which can be a substrate for fatal ventricular arrhythmias and subsequent sudden cardiac death. Although late gadolinium enhancement (LGE) on cardiac magnetic...
7.
Lumish H, Sherrid M, Janssen P, Ferrari G, Hasegawa K, Castillero E, et al.
J Am Coll Cardiol
. 2024 Oct;
84(20):1999-2011.
PMID: 39365226
Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Signaling pathways that link genetic sequence variants to clinically overt HCM and progression to severe forms of HCM remain...
8.
Liang L, Lumish H, Shimada Y, Weiner S
Clin Res Cardiol
. 2024 Jul;
PMID: 39083087
No abstract available.
9.
Liang L, Lumish H, Sewanan L, Shimada Y, Maurer M, Weiner S, et al.
J Card Fail
. 2024 May;
30(9):1136-1153.
PMID: 38777216
For many years, treatment of hypertrophic cardiomyopathy (HCM) has focused on non-disease-specific therapies. Cardiac myosin modulators (ie, mavacamten and aficamten) reduce the pathologic actin-myosin interactions that are characteristic of HCM,...
10.
Yasuda R, Osawa I, Goto T, Hasegawa K, Fifer M, Tower-Rader A, et al.
Circ Rep
. 2024 Mar;
6(3):74-79.
PMID: 38464986
Alcohol septal ablation (ASA) and septal myectomy (SM) are 2 options for septal reduction therapy (SRT) to treat medication-resistant symptomatic obstructive hypertrophic cardiomyopathy (HCM). Because differences in mortality rates after...